Resources Repository
-
ReviewWeb Portal 2016Use of Economics in Informing U.S. Public Health Policy
The goal of this American Journal of Preventive Medicine supplement on “The Use of Economics …
The goal of this American Journal of Preventive Medicine supplement on “The Use of Economics in Informing U.S. Public Health Policy” is to influence policy researchers to identify and undertake economic research that generates the key evidence needed to inform policy. In public health, economic evaluation, primarily cost and cost-effectiveness analysis, has been widely used to demonstrate the economic burden of health-related conditions and the value of proposed programs and policies. However, despite the wealth…
Costing Methods | Government/Law | Economics/Finance | North America | Priority Setting/Ethics | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Health/Medicine -
ArticlePublication 2015Population Health Model (POHEM): An Overview
This paper provides an overview of the rationale, methodology and applications of the Population Health …
This paper provides an overview of the rationale, methodology and applications of the Population Health Model (POHEM). POHEM is a health microsimulation model, developed at Statistics Canada in the early 1990s. The authors describe that POHEM draws together rich multivariate data from a wide range of sources to simulate the lifecycle of the Canadian population, specifically focusing on aspects of health. The model dynamically simulates individuals’ disease states, risk factors, and health determinants, in order…
Evidence Synthesis | Costing Methods | Economics/Finance | North America | Mathematical Models | Microsimulation | Calibration/Validation | Chronic Disease/Risk | Health Systems | Policy/Regulation | Clinical Care | Health/Medicine -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Evidence Synthesis | Government/Law | Economics/Finance | North America | Priority Setting/Ethics | Mathematical Models | Technology Assessment | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Energy/Engineering | Health/Medicine -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Evidence Synthesis | Economics/Finance | North America | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Culture/Society | Health/Medicine -
ArticleWeb Portal 2017PLoS Collection: Prevention, Diagnosis and Treatment of Sexually Transmitted Infections
Globally, the World Health Organization (WHO) estimates that more than one million new sexually transmitted …
Globally, the World Health Organization (WHO) estimates that more than one million new sexually transmitted infections (STIs) occur each day, incurring a very substantial burden of morbidity, mortality and additional infections. The pathogens responsible include bacteria, parasites and viruses, and intensive research is needed to address the substantial barriers to diagnosis and treatment of STIs, and the behavioral challenges of prevention. This PLOS collection, published in collaboration with WHO, focuses on global policy and systems…
Costing Methods | Economics/Finance | Latin America & Caribbean | Priority Setting/Ethics | Mathematical Models | Dynamic Transmission | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ArticleWeb Portal 2017PLOS Collection: Economic Efficiency of HIV Services
In order to maximize the value for money for HIV services and increase efficiency without …
In order to maximize the value for money for HIV services and increase efficiency without sacrificing quality, robust and up-to-date data on costs, efficiency and its determinants are needed. This PLOS collection, Economic Efficiency of HIV Services, presents recent, high-quality evidence from low- and middle-income countries on costs and technical efficiency of HIV services and their determinants. These data contribute to the current discussion on optimizing resources for HIV services and can provide programmatic guidance for…
Costing Methods | Economics/Finance | Latin America & Caribbean | Priority Setting/Ethics | Cost-Effectiveness Analysis | Operations Research | Infectious Diseases | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2017Cost Determinants of Routine Infant Immunization Services
The EPIC study collected data on routine infant immunization costs from Benin, Ghana, Honduras, Moldova, …
The EPIC study collected data on routine infant immunization costs from Benin, Ghana, Honduras, Moldova, Uganda, Zambia, using a standardized approach. The authors estimated how costs were distributed across budget categories and programmatic activities, and investigated how the cost structure of immunization sites varied by country and site characteristics. For each country, the economic costs of infant immunization were estimated by administrative level, budget category, and programmatic activity from a program perspective. Regression models were…
Costing Methods | Economics/Finance | Latin America & Caribbean | Infectious Diseases | Child/Nutrition | Health Systems | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2017Getting it Right When Budgets are Tight: Prioritizing Responses to HIV Epidemics
Prioritizing investments across health interventions is complicated by the nonlinear relationship between intervention coverage and …
Prioritizing investments across health interventions is complicated by the nonlinear relationship between intervention coverage and epidemiological outcomes. It can be difficult for countries to know which interventions to prioritize for greatest epidemiological impact, particularly when budgets are uncertain.The authors examined four case studies of HIV epidemics in diverse settings, each with different characteristics. These case studies were based on public data available for Belarus, Peru, Togo, and Myanmar. The Optima HIV model and software package…
Costing Methods | Economics/Finance | Latin America & Caribbean | Priority Setting/Ethics | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Costing Methods | Government/Law | North America | Benefit-Cost Analysis | Chronic Disease/Risk | Policy/Regulation | Health/Medicine